Table 3.
Detection of OGIgAB in paired CSF and serum samples from MS and control patients.
| Pattern I | Pattern II | Pattern III | Pattern II | |
|---|---|---|---|---|
| NonMSDND (n = 32) | 17.39% (4) | 8.70% (2) | 0% (0) | 73.91% (17) |
| NDND (n = 21) | 13.33% (4) | 10.00% (3) | 13.33% (4) | 66.33% (19) |
| MS (n = 151) | 21.90% (33) | 12.60% (19) | 30.50% (46) | 35.10% (53) |
| CIS (n = 56) | 16.10% (9) | 19.60% (11) | 46.40% (26) | 17.90% (10) |
| RRMS (n = 50) | 32.00% (16) | 6.00% (3) | 28.00% (14) | 34.00% (17) |
| SPMS (n = 24) | 20.80% (5) | 16.70% (24) | 20.80% (4) | 41.7% (10) |
| PPMS (n = 21) | 14.30% (3) | 4.80% (1) | 4.80% (1) | 76.20% (16) |
NonMSDND Non-MS demyelinating neurological diseases, NDND non-demyelinating neurological diseases, MS multiple sclerosis, CIS clinically isolated syndrome, RRMS relapsing–remitting multiple sclerosis.